LGND

Business Context and Reporting Period

Ligand Pharmaceuticals Inc. (Ligand) is a biotechnology company focused on drug discovery and early-stage development. This Form 10-Q covers the quarterly period ended March 31, 2011. The quarter was defined by the completion of the acquisition of CyDex Pharmaceuticals, Inc. on January 24, 2011, which added the CAPTISOL drug formulation platform and four marketed products to Ligand's portfolio. The company operates two reportable segments: the traditional biotech operations and the newly acquired CyDex business.

Key Financial Metrics

Note: Working capital is calculated as Total Current Assets ($31,296) minus Total Current Liabilities ($44,570).

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $9.5 million compared to a net loss of $2.8 million in the prior year. This reversal was primarily driven by a non-cash income tax benefit of $13.8 million resulting from the release of valuation allowances against deferred tax assets following the CyDex acquisition.
• Revenue Decline: Total revenues decreased 35% to $3.9 million. While royalties remained flat at $2.0 million, collaborative research and development revenues dropped significantly from $4.0 million to $0.9 million due to the termination of certain collaboration agreements. Material sales of $1.0 million were recorded for the first time due to the CyDex acquisition.
• Expense Reduction: Research and development expenses fell 73% to $2.0 million, largely due to the termination of collaboration costs and staff reductions. However, General and Administrative (G&A) expenses increased 37% to $4.2 million due to transaction costs and operating expenses associated with the CyDex acquisition.
• Balance Sheet Impact: Total assets increased from $75.6 million to $134.2 million, driven by the recognition of $76.8 million in goodwill and intangible assets from the CyDex deal. Conversely, the company moved from positive working capital to a deficit of $13.3 million due to increased current liabilities, including new debt and lease obligations.

Guidance, Outlook, and Risks

Liquidity and Capital Resources: Management believes that available cash, cash equivalents, short-term investments ($16.5 million total), and future royalty revenues will be sufficient to satisfy operating and capital requirements for at least the next twelve months. However, the company maintains a working capital deficit and relies on future milestone and royalty payments.

Debt Obligations: To fund the CyDex acquisition, Ligand entered into a $20 million term loan (Oxford Loan) with interest-only payments for one year at 8.64%. Additionally, a $5 million cash-collateralized revolving line of credit (Square 1 Loan) was established. In April 2011 (subsequent event), the revolving line was increased to $10 million.

Key Risks and Contingencies:

• Contingent Value Rights (CVRs): The company recorded a $19.2 million liability for CVRs issued to CyDex shareholders, with potential additional payments of up to $7.25 million based on milestones and revenue sharing. A $1.7 million increase in CVR liability was recorded in Q1 2011.
• AVINZA Liability: Ligand remains liable to Organon for AVINZA royalties if King Pharmaceuticals defaults. The fair value of this obligation is approximately $30.1 million.
• Integration Risks: Significant challenges exist in integrating CyDex's operations and CAPTISOL technology. The company relies on a sole-source supplier for CAPTISOL, creating supply chain vulnerability.
• Patent Expirations: Initial CAPTISOL patents expire in 2010 in the U.S., though newer patents extend protection through 2025 and 2029. Generic competition poses a risk to royalty revenues.

Investor Verification Checklist

• Verify the sustainability of the $13.8 million income tax benefit, which was a one-time non-cash item driven by the CyDex acquisition accounting.
• Monitor the company's ability to service its new $25 million debt load and maintain the $10 million cash covenant required by the CyDex CVR agreement.
• Assess the progress of the CyDex integration and the realization of revenue from the CAPTISOL platform, given the reliance on a sole-source supplier.
• Review the status of the AVINZA patent litigation against generic manufacturers (Actavis and Sandoz), as an adverse judgment could significantly impact future royalty revenues.
• Track the fair value fluctuations of the Contingent Value Rights (CVRs) liabilities, which can materially impact reported earnings.